A clinician-scientist from Massachusetts Eye and Ear performed the first Luxturna gene therapy treatment since its FDA approval in December, the institution announced in a press release.
The procedure was performed on March 20 on a 13-year-old New Jersey boy by Jason Comander, MD, PhD, the release said.
Developed by Spark Therapeutics, Luxturna (voretigene neparvovec-rzyl) improves visual function in individuals with inherited retinal disease caused by mutations in the RPE65 gene. The procedure includes injecting a modified virus into the eye to correct a deficiency caused by the mutations.
“It
Uncategorized